Cystic Fibrosis News Today Daily Digest

Cystic Fibrosis Weekly Update Contents: First Patients Enrolled in Phase 2b Trial Testing MS1819 for Exocrine Pancreatic Insufficiency in CF First Patients Enrolled in Phase 2b Trial Testing MS1819 for Exocrine Pancreatic Insufficiency in CF Aug 17, 2020 07:00 am | Forest Ray AzurRx BioPharma has enrolled the first three patients in its Phase 2b trial investigating MS1819 as a treatment for exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. The trial, dubbed OPTION 2 (NCT04375878), aims to enroll 30 CF patients ages 18 and older. Top-line data from the trial is expected in the first half […] The post First Patients Enrolled in Phase 2b Trial Testing MS1819 for Exocrine Pancreatic Insufficiency in CF appeared first on Cystic Fibrosis News Today. Read More Recent News A Giant Win After a Big Loss MS1819-PERT Combo Shows Benefits for CF Patients With EPI in Phase 2 Trial First Participants Dosed in Early Clinical Trial of Inhaled Therapy ARO-ENaC Cystic Fibrosis Ireland Establishes Grants for Personal Protective Equipment Does Everyone With CF Have Body Dysmorphia?